Genetic Technologies Updates on COVID Severity Risk Test, Expansion

 Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Germline Testing division.

Key Highlights

• Total COVID-19 positive patient data analyzed exceeds 5,500 following inclusion of further 4,000 patients’ data
  º Predictive capabilities improved 100% over age and sex alone1
  º Analysis confirms that the test is well calibrated2
  º Further datasets will continue to enhance the accuracy and consistency of the algorithm

• Anticipate submission for regulatory clearance via Centers for Medicare and Medicaid Services/Clinical Laboratory Improvement Amendments (CMS/CLIA) by the end of Q1 CY21 following final validation process of expanded dataset

• In active conversations on commercialization opportunities in conjunction with CLIA regulatory submission and clearance

• Additionally, as previously announced, the Company has commenced with equipment calibration along with specialized inhouse training of the scientific team to establish the Germline Testing division for hereditary cancer risk with initial focus on:
  º BRCA testing to be offered in conjunction with GeneType for Breast Cancer, and
  º Lynch Syndrome testing to be offered in conjunction with GeneType for Colorectal Cancer

The Company will provide an update on further advancements to its diagnostic tests and hold an investor webinar to discuss the quarterly update, on Thursday, January 28, 2021 at 11:30 AEDT.

To participate on the quarterly investor webinar, please register at: https://us02web.zoom.us/webinar/register/WN_gy5DGFNMSKiAYfYeV0Ygpg

https://finance.yahoo.com/news/genetic-technologies-provides-covid-19-120000548.html